July 24, 2014 4:59 PM ET

Pharmaceuticals

Company Overview of Taisho Pharmaceutical Co., Ltd.

Company Overview

Taisho Pharmaceutical Co., Ltd. develops, manufactures, and sells over-the counter medications, prescription pharmaceuticals, and health-care-related products. The company offers its products in the areas of CNS, diabetes, immunology/allergy, and infectious diseases. It also provides health information through community pharmacies and drugstores. It sells its products through its subsidiaries in Hong Kong, Taiwan, Malaysia, the Philippines, Indonesia, Thailand, Vietnam, China, Australia, the United States, and the United Kingdom. The company was founded in 2011 and is based in Tokyo, Japan. Taisho Pharmaceutical Co., Ltd. operates as a subsidiary of Taisho Pharmaceutical Holdings Co., Ltd.

3-24-1, Takada

Toshima-ku

Tokyo,  170-8633

Japan

Founded in 2011

Phone:

81 3 3985 1111

Fax:

81 3 3985 8627

Key Executives for Taisho Pharmaceutical Co., Ltd.

President and Director
Executive Vice President and Director
Managing Director and Director
Managing Director and Director
Executive Director
Compensation as of Fiscal Year 2014.

Taisho Pharmaceutical Co., Ltd. Key Developments

Taisho Announces Encouraging Results from Two Phase III Diabetes Trials

Taisho Pharmaceutical Co., Ltd. has announced results from Phase III long-term administration clinical trials of the SGLT2 inhibitor luseogliflozin hydrate. The results were presented for the two Phase III clinical trials conducted in respect of Japanese Type 2 diabetes patients who cannot adequately control their blood glucose levels with the existing oral hypoglycemic agents. The clinical trials comprised Study-1, a long-term administration clinical trial in combined use with sulfonylurea glimepiride, and Study-2, a long-term administration clinical trial in combined use with 5 types of existing oral hypoglycemic agents. Study-1 targeted 221 Japanese Type 2 diabetes patients who cannot adequately control their blood glucose levels with sulfonylurea glimepiride. They were orally administered 2.5 mg of luseogliflozin or a placebo once daily for 24 weeks in a double blind trial. The results showed that the luseogliflozin significantly lowered the hemoglobin A1c (HbA1c), the study's primary endpoint.

Taisho Pharmaceutical Co., Ltd. Announces Results from Phase III Diabetes Trials

Taisho Pharmaceutical Co., Ltd. has announced the results of Phase III clinical trials in Japan of the SGLT2 inhibitor luseogliflozin hydrate. The following two Phase III clinical trials targeting Japanese Type 2 diabetes mellitus patients: a placebo-controlled double-blind study ("Study-1") and a monotherapy, long-term treatment study ("Study-2"). Study-1: In this Phase III, a double-blind, placebo-controlled study targeting 158 Japanese Type 2 diabetes mellitus patients, either 2.5 mg of luseogliflozin or a placebo was administered orally once daily for 24 weeks. The study confirmed that luseogliflozin significantly reduced hemoglobin A1c (HbA1c), the study's primary endpoint. At the time of completing drug administration, the difference between the HbA1c reduction from the baseline and the placebo was -0.75%.

Taisho Pharmaceutical Co., Ltd. Presents at BioJapan 2013 World Business Forum, Oct-09-2013

Taisho Pharmaceutical Co., Ltd. Presents at BioJapan 2013 World Business Forum, Oct-09-2013 . Venue: Pacifico Yokohama, Yokohama, Japan.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
July 31, 2013
Biofermin Pharmaceutical Co., Ltd.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Taisho Pharmaceutical Co., Ltd., please visit www.taisho.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.